Unjha Formulations Ltd

On 04-Mar, Unjha Formulations Ltd witnessed a notable decline in its share price, closing at ₹20.08, down ₹0.92 or 4.38% from the previous session. This drop reflects a continuation of recent negative momentum, with the stock nearing its 52-week low and underperforming both its sector and broader market benchmarks.

Unjha Formulations Ltd closed the week ending 6 February 2026 with a 4.32% gain, outperforming the Sensex’s 1.51% rise over the same period. Despite this positive price movement, the company reported flat quarterly financial performance amid margin compression, reflecting ongoing challenges in sustaining growth. The week was marked by a steady upward trend in the stock price, supported by moderate volumes and mixed market sentiment.

Unjha Formulations Ltd's latest results show mixed performance; while net sales increased by 17.29% year-on-year to ₹4.41 crores, net profit plummeted by 70.73% quarter-on-quarter to ₹0.24 crores, indicating significant operational challenges and margin compression. Despite a strong return on equity of 32.48%, the company's profitability issues raise concerns about its operational efficiency and growth potential.

Unjha Formulations Ltd will announce its results on 04 February 2026.

Unjha Formul's historical performance has shown fluctuations in net sales and profits, with net sales decreasing to 13.86 Cr in March 2025 from 18.50 Cr in March 2024, but profit after tax increased to 0.41 Cr. Despite volatility, the company improved its profitability metrics and shareholder equity during this period.

As of 19-Nov, Unjha Formulations Ltd is priced at 26.40, with a recent short-term performance showing a 6.02% return over one week and 9.91% over one month, significantly outperforming the Sensex. However, a sharp decline in delivery volume raises concerns about the sustainability of this price increase, and the stock has a year-to-date decline of 13.13%.

As of 13-Nov, Unjha Formulations Ltd's stock price has risen to Rs 26.99, reflecting an 8.39% increase, and has outperformed its sector significantly. Despite a recent decline in investor participation, the stock shows strong long-term growth potential with a 166.70% increase over three years.

As of November 12, 2025, Unjha Formul. is considered undervalued with a PE ratio of 11.08 and a PEG ratio of 0.40, significantly outperforming peers like Sun Pharma. and Divi's Lab., and demonstrating strong long-term returns of 149.21% over three years and 250.28% over five years, despite recent underperformance year-to-date.

Unjha Formul's historical performance shows fluctuating net sales, decreasing from 18.50 Cr in Mar'24 to 13.86 Cr in Mar'25, but profitability metrics improved, with profit after tax rising to 0.41 Cr and earnings per share increasing to 0.92, indicating enhanced operational efficiency.

Unjha Formul's historical performance shows declining net sales from 18.50 Cr in March 2024 to 13.86 Cr in March 2025, but profitability metrics improved, with profit after tax rising from 0.28 Cr to 0.41 Cr and EPS increasing from 0.62 to 0.92. Overall, the company faces sales challenges while demonstrating better operational efficiency.

As of 10-Nov, Unjha Formulations Ltd is seeing a price increase to Rs 25.55, up 8.26%, with strong short-term performance but declining investor participation. Despite outperforming the Sensex recently, the stock has underperformed year-to-date, indicating potential concerns for future momentum.